Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1999 • 5,659 citations

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 • 3,172 citations

Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance

2004 • 2,910 citations

Multiple Sclerosis

2000 • 2,813 citations

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

2010 • 2,531 citations

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

2004 • 2,462 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

2010 • 2,146 citations

Hypertension in mice lacking the gene for endothelial nitric oxide synthase

1995 • 2,075 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue

2001 • 1,922 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 1,908 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Multiple sclerosis

2002 • 1,678 citations

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

2002 • 1,655 citations

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

2007 • 1,595 citations

The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors

2002 • 1,478 citations

THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY

1989 • 1,387 citations

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

1993 • 1,227 citations

The natural history of multiple sclerosis:a geographically based study

1999 • 1,190 citations

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

2006 • 1,043 citations

Visualizing the generation of memory CD4 T cells in the whole body

2001 • 1,029 citations

The Duration of Antigenic Stimulation Determines the Fate of Naive and Effector T Cells

1998 • 890 citations

Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate

2007 • 861 citations

Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines: Table 1.

2002 • 812 citations

Dynamics of T Lymphocyte Responses: Intermediates, Effectors, and Memory Cells

2000 • 807 citations

Essential Role for Sphingosine Kinases in Neural and Vascular Development

2005 • 719 citations

Phenotype and function of human T lymphocyte subsets: Consensus and issues

2008 • 702 citations

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

2001 • 697 citations

The prevalence of multiple sclerosis in the world: an update

2001 • 661 citations

Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions

2009 • 639 citations

Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate

2004 • 619 citations

European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

2001 • 595 citations

FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. I. FTY720 Selectively Decreases the Number of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing

1998 • 586 citations

Finding a way out: lymphocyte egress from lymphoid organs

2007 • 573 citations

Serine Palmitoyltransferase Is the Primary Target of a Sphingosine-like Immunosuppressant, ISP-1/Myriocin

1995 • 537 citations

The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors

2004 • 532 citations

Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology

2007 • 524 citations

Protective Effects of Sphingosine 1-Phosphate in Murine Endotoxin-induced Inflammatory Lung Injury

2004 • 491 citations

FTY720: Sphingosine 1-Phosphate Receptor-1 in the Control of Lymphocyte Egress and Endothelial Barrier Function

2004 • 462 citations

Cellular mechanisms of IL‐17‐induced blood‐brain barrier disruption

2009 • 452 citations

Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration

2004 • 436 citations

Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling

2005 • 429 citations

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

2009 • 429 citations

Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning

2009 • 420 citations

Effect of relapses on development of residual deficit in multiple sclerosis

2003 • 412 citations

S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell Egress

2008 • 406 citations

Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo

2006 • 400 citations

Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor

2007 • 394 citations

Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability

2003 • 375 citations

G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation

2003 • 373 citations

FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory

2000 • 364 citations

Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors

2009 • 350 citations

Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes

2004 • 329 citations

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

2008 • 326 citations

Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival

2005 • 325 citations

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS

2007 • 323 citations

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

2007 • 316 citations

Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720

1995 • 306 citations

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

2005 • 298 citations

Priming of Memory But Not Effector CD8 T Cells by a Killed Bacterial Vaccine

2001 • 294 citations

Antagonism of Sphingosine-1-Phosphate Receptors by FTY720 Inhibits Angiogenesis and Tumor Vascularization

2006 • 288 citations

Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune Encephalomyelitis

2010 • 281 citations

Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment

2003 • 281 citations

Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses

2005 • 278 citations

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

2002 • 272 citations

FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity

2002 • 265 citations

Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720

2005 • 263 citations

FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. II. FTY720 Prolongs Skin Allograft Survival by Decreasing T Cell Infiltration into Grafts But Not Cytokine Production In Vivo

1998 • 263 citations

Expression of CCR7 in multiple sclerosis: Implications for CNS immunity

2004 • 263 citations

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

2010 • 257 citations

FTY720 modulates human oligodendrocyte progenitor process extension and survival

2007 • 251 citations

Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice

2004 • 221 citations

FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

2005 • 219 citations

FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation

2004 • 216 citations

Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL

2005 • 212 citations

In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights

2004 • 207 citations

Common Signaling Pathways Link Activation of Murine PAR-1, LPA, and S1P Receptors to Proliferation of Astrocytes

2003 • 204 citations

Essential Roles of Sphingosine 1-Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury

2006 • 199 citations

Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions

2010 • 193 citations

Oral fingolimod (FTY720) in multiple sclerosis

2009 • 193 citations

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

2010 • 191 citations

VEGF induces S1P ₁ receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors

2003 • 190 citations

Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells

2008 • 188 citations

Migration and Function of Antigen-Primed Nonpolarized T Lymphocytes in Vivo

2001 • 176 citations

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

2010 • 170 citations

FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation

2000 • 166 citations

Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics

2010 • 163 citations

The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein-Gated Potassium Channel IKACh

2005 • 162 citations

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

2009 • 161 citations

FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis

2007 • 157 citations

Identification of Edg1 Receptor Residues That Recognize Sphingosine 1-Phosphate

2000 • 155 citations

Tipping the gatekeeper: S1P regulation of endothelial barrier function

2007 • 150 citations

Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer

2005 • 149 citations

Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

2008 • 148 citations

G protein regulation of cardiac muscarinic potassium channel

1995 • 145 citations

Interferon in relapsing-remitting multiple sclerosis

2001 • 144 citations

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

2006 • 143 citations

Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia

2009 • 143 citations

FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood‐Brain‐Barrier Damage

2008 • 142 citations

The Immune Modulator FTY720 Inhibits Sphingosine-1-phosphate Lyase Activity

2005 • 137 citations

Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors

2007 • 136 citations

Immunosuppressant FTY720 inhibits thymocyte emigration

2000 • 135 citations

FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats.

1996 • 127 citations

Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720

2003 • 126 citations

CC Chemokine Receptor 7–dependent and –independent Pathways for Lymphocyte Homing

2001 • 126 citations

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study

2003 • 126 citations

Regulation of Endothelial Barrier Function

2011 • 123 citations

Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes

2001 • 122 citations

A new immunosuppressant, FTY720, induces bcl‐2‐associated apoptotic cell death in human lymphocytes

1996 • 121 citations

Cell Type-specific Localization of Human Cardiac S1P Receptors

2002 • 120 citations

Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720

2003 • 119 citations

In Vivo Priming of Cd4 T Cells That Produce Interleukin (Il)-2 but Not IL-4 or Interferon (Ifn)-γ, and Can Subsequently Differentiate into IL-4–Or IFN-γ–Secreting Cells

2001 • 113 citations

Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging

2004 • 109 citations

Activation of muscarinic K+ current in guinea‐pig atrial myocytes by sphingosine‐1‐phosphate.

1995 • 106 citations

In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology

2005 • 105 citations

Sphingosine-1-phosphate and modulation of vascular tone

2009 • 104 citations

VEGF and vascular changes in chronic neuroinflammation

2003 • 97 citations

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

2010 • 95 citations

Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes

2003 • 94 citations

Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease

2008 • 94 citations

The identification of myriocin-binding proteins

1999 • 94 citations

VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE

2009 • 92 citations

The 5-year direct medical cost of neonatal and childhood stroke in a population-based cohort

2010 • 91 citations

FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression

2001 • 90 citations

Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720

1996 • 87 citations

Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720

2005 • 85 citations

Sphingosine 1‐phosphate induces the production of glial cell line‐derived neurotrophic factor and cellular proliferation in astrocytes

2002 • 81 citations

S1P inhibits gap junctions in astrocytes: involvement of G_i and Rho GTPase/ROCK

2006 • 77 citations

Balance of S1P₁and S1P₂signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature

2008 • 75 citations

FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves

2008 • 70 citations

Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis

2010 • 70 citations

Lysophospholipid receptors in vertebrate development, physiology, and pathology

2008 • 70 citations

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

2010 • 62 citations

Sphingosine 1-phosphate pathway therapeutics: a lipid ligand–receptor paradigm

2003 • 56 citations

Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects

2007 • 50 citations

FTY720 attenuates lesional interleukin‐17⁺ cell accumulation in rat experimental autoimmune neuritis

2009 • 46 citations

Overview of FTY720 Clinical Pharmacokinetics and Pharmacology

2004 • 44 citations

FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects

2001 • 43 citations

Treating multiple sclerosis with monoclonal antibodies: a 2010 update

2010 • 39 citations

Identification of Leu276 of the S1P₁Receptor and Phe263 of the S1P₃Receptor in Interaction with Receptor Specific Agonists by Molecular Modeling, Site-Directed Mutagenesis, and Affinity Studies

2006 • 37 citations

CRITICAL VASOSPASM DURING FINGOLIMOD (FTY720) TREATMENT IN A PATIENT WITH MULTIPLE SCLEROSIS

2010 • 37 citations

Recovery from EAE is associated with decreased survival of encephalitogenic T cells in the CNS of B7‐1/B7‐2‐deficient mice

2003 • 37 citations

Protective Effects of Early CD4+ T Cell Reduction in Hepatic Ischemia/Reperfusion Injury

2009 • 34 citations

The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects

2008 • 33 citations

Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine

2008 • 33 citations

Lysophospholipid Activation of G Protein-Coupled Receptors

2008 • 32 citations

Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure

2008 • 31 citations

Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat

2002 • 28 citations

A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod

2008 • 16 citations

Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes

2007 • 15 citations

Update on the treatment options for multiple sclerosis

2009 • 15 citations

Intravital 2-photon imaging of encephalitogenic effector cells during fingolimod (FTY720) treatment of experimental autoimmune encephalomyelitis

2008 • 4 citations

Oral Therapy with FTY720 Inhibits Angiogenesis in the Spinal Cord of Lewis Rats in the Relapse Phase of Experimental Autoimmune Encephalomyelitis

2007 • 1 citations